ERBB2 and breast carcinoma: On the contrary, we analyzed only one breast cancer subtype (HER2-overexpressing) and selected only early breast cancer patients to whom radical local therapy was applied, followed by trastuzumab and chemotherapy/hormonotherapy in the adjuvant setting, which is linked with a relatively good overall prognosis [55,56].